Status:
COMPLETED
Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
Lead Sponsor:
Kyoto University
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
25-75 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether low-dose peg-interferon plus ribavirin therapy is effective in the prevention of hepatocellular carcinoma (HCC) in patients who had the curative resec...
Eligibility Criteria
Inclusion
- Clinical diagnosis of Hepatocellular carcinoma due to Chronic Hepatitis C Virus Infection.
- Must be treated with curative treatment for primary tumor using either surgical resection or radiofrequency ablation therapy
Exclusion
- No recurrence of hepatocellular carcinoma 3 months after the primary treatment
- Renal dysfunction
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00375661
Start Date
September 1 2006
End Date
March 1 2013
Last Update
September 2 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Gastroenterology and Hepatology, Kyoto University Hospital
Kyoto, Japan
2
Osaka Red Cross Hospital
Osaka, Japan